Biotechnology Value Fund L P's Form 4 filing
Eledon Pharmaceuticals, Inc. (ELDN) · filed Oct 31, 2024
- Accession no.
- 0000921895-24-002408
- Filed
- Oct 31, 2024, 5:52 PM ET
- Trade date
- Oct 29, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 0 non-derivative transactions and 3 derivative transactions. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Biotechnology Value Fund L PCIK 0000918923 | Other: See Explanation of Responses |
| BVF Partners L PCIK 0001055947 | 10% Owner |
| BVF IncCIK 0001056807 | 10% Owner |
| Biotechnology Value Fund II LPCIK 0001102444 | Other: See Explanation of Responses |
| Lampert Mark NCIK 0001233840 | 10% Owner |
| Biotechnology Value Trading Fund OS LPCIK 0001660683 | Other: See Explanation of Responses |
| BVF Partners OS Ltd.CIK 0001660684 | Other: See Explanation of Responses |
| BVF I GP LLCCIK 0001803805 | Other: See Explanation of Responses |
| BVF II GP LLCCIK 0001803806 | Other: See Explanation of Responses |
| BVF GP Holdings LLCCIK 0001803809 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 29, 2024 | Common Stock, $0.001 par value | PPurchaseAcquired | +2,213,816 | $3.65 | +$8,078,214.58 | 7,415,596 | Direct | |
| Oct 29, 2024 | Common Stock, $0.001 par value | PPurchaseAcquired | +2,100,244 | $3.65 | +$7,663,790.36 | 6,235,545 | Direct | |
| Oct 29, 2024 | Common Stock, $0.001 par value | PPurchaseAcquired | +440,489 | $3.65 | +$1,607,344.36 | 838,507 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.